---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341315"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2026-08-10T12:06:21+00:00"
generated_at: "2026-08-10T12:10:33.547792+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cogent reports Q2 net loss $96.4M; bezuclastinib PDUFA dates set for Nov/Dec 2026

## Summary
- Net loss $96.4M vs $73.5M in Q2 2025; R&D $70.8M, G&A $31.8M.
- Cash $792.3M at June 30, 2026; pro forma $865.9M with $73.6M ATM proceeds, funds into late 2028.
- FDA accepted NDA for bezuclastinib+sunitinib in GIST with priority review; PDUFA Nov 30, 2026.
- AdvSM NDA submitted June 30; NonAdvSM PDUFA Dec 30, 2026; APEX trial 65% ORR.
- PEAK trial: HR 0.50, mPFS 16.5 vs 9.2 months, ORR 46% vs 26%.

## SEC filing metadata
- accession: 0001193125-26-341315
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2026-08-10T12:06:21+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/0001193125-26-341315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341315
- JSON: https://secwatch.observer/filing/0001193125-26-341315.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.